Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DD-S052P in healthy volunteers
NCT07347223Phase 1Completed
- Sponsor
- HLB SCIENCE Inc.
- Start
- Jul 2023
- Primary completion
- May 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in sepsis comparing DD-S052P with Placebo (2 arms). Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events at Day 14, Change From Baseline in Vital Signs at Day 14 and 2 more. Started Jul 2023; status: completed.
02
Drugs
DD-S052P
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT07347223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347223.